ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
23 August 2023 - 2:00PM
Business Wire
Global intellectual property portfolio now
stands at 67 issued patents
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the
issuance of three new patents, one in the U.S. and two in Europe.
ENDRA’s intellectual property portfolio now includes 67 issued
patents worldwide, providing protection for the TAEUS® system with
its novel hybrid ultrasound and thermoacoustic imaging
technology.
The following three patents strengthening the TAEUS system’s
proprietary position were issued:
- U.S. Patent No. 11730374, titled “Radio Frequency Applicator
for a Thermoacoustic Imaging System,” relates to a novel radio
frequency applicator with an integrated wedge. The integrated wedge
minimizes unwanted signals emanating from a patient’s skin, while
maximizing radio frequency energy delivery to a patient’s targeted
region of interest.
- European Patent No. 3902495, titled “Method and System for
Monitoring Tissue Temperature,” relates to a novel method and
system for monitoring tissue temperature during surgical procedures
by utilizing ENDRA’s TAEUS system. ENDRA expects its method and
system to be effective for both thermotherapy and cryotherapy
procedures. This patent is linked to its parent, U.S. Patent No.
10631734B1.
- European Patent No. 3806721, titled “Method and System for
Determining Fractional Fat Content of Tissue,” covers a method and
system for determining fractional fat content of tissue that takes
into consideration the speed of sound in that tissue. This patent
builds upon ENDRA's issued patents in the area of tissue fat
quantification. Conventional ultrasound image formation
methodologies assume a single speed of sound, while this issued
patent leverages TAEUS' inherent sensitivity to fractional fat
differences in tissue to estimate the actual speed of sound in
tissue and thereby improves the accuracy of TAEUS fat
quantification methodologies. The patent also describes a
calibration methodology for fractional fat measurements, and is
linked to its parent, U.S. Patent No. 10258277B2.
“These issued patents in two key geographies advance and protect
ENDRA's thermoacoustic imaging systems in areas with high unmet
clinical need," stated ENDRA's Chairman and Chief Executive Officer
Francois Michelon. "Currently, our portfolio includes 67 issued
patents globally.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
the more than 700,000 ultrasound systems in use globally today.
TAEUS® is initially focused on the measurement of fat in the liver
as a means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver
conditions that affect over two billion people globally, and for
which there are no practical diagnostic tools. Beyond the liver,
ENDRA is exploring several other clinical applications of TAEUS®,
including visualization of tissue temperature during energy-based
surgical procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” “anticipate,” “attempt,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“hope,” “intend,” “may,” “plan,” “possible,” “potential,”
“project,” “seek,” “should,” “will,” “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches;
statements relating to future financial position and projected
costs and revenue; expectations concerning ENDRA’s business
strategy; and statements regarding ENDRA’s ability to find and
maintain development partners. Forward-looking statements involve
inherent risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements as a
result of various factors including, among others: the ability to
raise additional capital in order to continue as a going concern;
the ability to obtain regulatory approvals necessary to sell ENDRA
medical devices in certain markets in a timely manner, or at all;
the ability to develop a commercially feasible technology and its
dependence on third parties to design and manufacture its products;
the impact of COVID-19 on ENDRA’s business plans; the ability to
find and maintain development partners; market acceptance of
ENDRA’s technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the SEC. You should not rely upon forward-looking
statements as predictions of future events. The forward-looking
statements made in this press release speak only as of the date of
issuance, and ENDRA assumes no obligation to update any such
forward-looking statements to reflect actual results or changes in
expectations, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230823322508/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
Von Sep 2023 bis Sep 2024